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A  74-year-old man with a  history of long-lasting 
persistent atrial fibrillation (AF) on chronic dabigatran 
treatment (2 × 150 mg/day) was referred for left atrial 
appendage (LAA) closure following a  severe ischemic 
stroke 2 years before. The patient was at high throm-
boembolic risk with a  CHA
2DS2-VASc score of 7 points 
(1 point for congestive heart failure, age, arterial hyper-
tension, diabetes mellitus, peripheral vascular disease 
and 2 points for the previous stroke) and HAS-BLED of 
3 points (1 point for hypertension, stroke and elderly). 
On admission, 2 days before the planned procedure, ECG 
showed sinus rhythm. Computed tomography confirmed 
favorable anatomy for epicardial LAA closure (Figure 1 A). 
Dabigatran was discontinued 3 days before the proce-
dure, and low-molecular-weight heparin was started 
(2 × 80 mg/day, the last dose on the day of the procedure). 
Before starting anesthesia at 3.57 PM the patient 
was confirmed with no thrombus in LAA by transesoph-
ageal echocardiography (TEE) (Figure 1 B). At that time, 
the patient started to experience AF. Just before start-
ing the LAA epicardial exclusion at 4:27 PM TEE was re-
peated. Fresh thrombus formation in LAA was observed 
(Figure 1 C). At 4:31 PM even more solid thrombus was 
noted (Figure 1 D). The patient was excluded from LAA 
closure. A  high-dose bolus of unfractionated heparin 
(10,000 U) was given, followed by infusion of 2000 U/h 
with a hope to resolve the thrombus by the next day. Next 
day at 10.30 AM another TEE was performed and par-
tial dilution of the thrombus was confirmed (Figure 1 E). 
No stroke, transient ischemic attack, or embolism was 
noted. Due to the high risk of thromboembolic events, 
the patient was discharged home with low-molecu-
lar-weight heparin (2 × 80 mg/day) and dabigatran 
(2 × 150 mg/day). After 2 months, TEE presented no 
signs of thrombus in the LAA. The patient underwent 
uncomplicated closed-chested LAA ligation with the 
LARIAT suture delivery device (SentreHEART, Inc., Red-
wood City, CA). Complete LAA closure was confirmed 
with TEE and contrast fluoroscopy. The patient did 
well after the procedure and was discharged on aspirin 
(150 mg/day) without any additional oral anticoagula-
tion treatment. A follow-up TEE performed at 3 months 
revealed a closed LAA with no leaks. After 3 years, the 
patient was on no anti-platelet or anti-thrombin medi-
cations with no signs of recurrent thromboembolic com-
plications.
The LAA is a  source of more than 90% of thrombus 
in AF and changes in cardiac rhythm from sinus rhythm 
to AF may particularly increase the risk of thrombus for-
mation in LAA. Oral anticoagulation is recommended as 
a  standard treatment to prevent thromboembolic events 
in AF patients. However, in patients who are at high risk 
for thrombus formation, new therapeutic options might be 
considered. One of them is LAA closure, which has become 
an alternative treatment for AF patients [1, 2]. One possi-
ble option is percutaneous epicardial LAA closure using the 
LARIAT system, which was shown to be effective in throm-
boembolism risk reduction, even in high-risk patients [3–5]. 
This case report describes rapid thrombus formation 
in LAA despite recommended oral anticoagulant treat-
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Figure 1. A – 3D computed tomography reconstruction scan with measurements of the left atrial appendage 
(LAA), B – transesophageal echocardiogram (TEE) at 3.57 PM with no thrombus in LAA (arrow), C – TEE at 4.27 
PM with a fresh thrombus formed in less than 20 min, D – TEE at 4.31 PM with a solid fresh thrombus in the 
LAA, E – TEE the next day with partial dilution of the LAA thrombus
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ment. In such a  case, epicardial LAA closure should be 
considered for effective thromboembolic protection.
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